Subtyping of Triple-Negative Breast Cancer: Implications for Therapy

被引：268

作者：

Abramson, Vandana G. ^{[1
,2
]}

Lehmann, Brian D. ^{[2
,3
]}

Ballinger, Tarah J. ^{[1
]}

Pietenpol, Jennifer A. ^{[2
,3
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA

[3] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Biochem, Nashville, TN 37232 USA

来源：

CANCER | 2015年 / 121卷 / 01期

基金：

美国国家卫生研究院;

关键词：

triple-negative breast cancer; targeted therapies; subtyping triple-negative breast cancer; clinical trials; INVASIVE DUCTAL CARCINOMA; RANDOMIZED PHASE-II; DNA-REPAIR DEFECT; POLY(ADP-RIBOSE) POLYMERASE; PIK3CA MUTATIONS; BASAL; IDENTIFICATION; CHEMOTHERAPY; CARBOPLATIN; METASTASIS;

D O I：

10.1002/cncr.28914

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple-negative breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified 6 distinct TNBC subtypes, each of which displays a unique biology. Exploring novel approaches for the treatment of these subtypes is critical, especially because the median survival for women with metastatic TNBC is less than 12 months, and virtually all women with metastatic TNBC ultimately will die of their disease despite systemic therapy. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard treatment. In this review, the authors discuss recent developments in subtyping TNBC and the current and upcoming therapeutic strategies being explored in an attempt to target TNBC. Cancer 2015;121:8-16. (c) 2014 American Cancer Society. Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment options and no approved targeted therapies. This review outlines the current knowledge about TNBC and strategies being explored to specifically target this disease.

引用

页码：8 / 16

页数：9

共 52 条

[1] Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array [J].

Andre, Fabrice ;

Job, Bastien ;

Dessen, Philippe ;

Tordai, Attila ;

Michiels, Stefan ;

Liedtke, Cornelia ;

Richon, Catherine ;

Yan, Kai ;

Wang, Bailang ;

Vassal, Gilles ;

Delaloge, Suzette ;

Hortobagyi, Gabriel N. ;

Symmans, W. Fraser ;

Lazar, Vladimir ;

Pusztai, Lajos .

CLINICAL CANCER RESEARCH, 2009, 15 (02) :441-451

[2]

[Anonymous], CANC RES

[3] Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer [J].

Arnes, JB ;

Brunet, JS ;

Stefansson, I ;

Bégin, LR ;

Wong, N ;

Chappuis, PO ;

Akslen, LA ;

Foulkes, WD .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4003-4011

[4] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

[5] How basal are triple-negative breast cancers? [J].

Bertucci, Francois ;

Finetti, Pascal ;

Cervera, Nathalie ;

Esterni, Benjamin ;

Hermitte, Fabienne ;

Viens, Patrice ;

Birnbaum, Daniel .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) :236-240

[6] Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers [J].

Byrski, T. ;

Gronwald, J. ;

Huzarski, T. ;

Grzybowska, E. ;

Budryk, M. ;

Stawicka, M. ;

Mierzwa, T. ;

Szwiec, M. ;

Wisniowski, R. ;

Siolek, M. ;

Narod, S. A. ;

Lubinski, J. .

BREAST CANCER RESEARCH AND TREATMENT, 2008, 108 (02) :289-296

[7] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].

Carey, Lisa A. ;

Perou, Charles M. ;

Livasy, Chad A. ;

Dressler, Lynn G. ;

Cowan, David ;

Conway, Kathleen ;

Karaca, Gamze ;

Troester, Melissa A. ;

Tse, Chiu Kit ;

Edmiston, Sharon ;

Deming, Sandra L. ;

Geradts, Joseph ;

Cheang, Maggie C. U. ;

Nielsen, Torsten O. ;

Moorman, Patricia G. ;

Earp, H. Shelton ;

Millikan, Robert C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502

[8] TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer [J].

Carey, Lisa A. ;

Rugo, Hope S. ;

Marcom, P. Kelly ;

Mayer, Erica L. ;

Esteva, Francisco J. ;

Ma, Cynthia X. ;

Liu, Minetta C. ;

Storniolo, Anna Maria ;

Rimawi, Mothaffar F. ;

Forero-Torres, Andres ;

Wolff, Antonio C. ;

Hobday, Timothy J. ;

Ivanova, Anastasia ;

Chiu, Wing-Keung ;

Ferraro, Madlyn ;

Burrows, Emily ;

Bernard, Philip S. ;

Hoadley, Katherine A. ;

Perou, Charles M. ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2615-2623

[9] Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype [J].

Cheang, Maggie C. U. ;

Voduc, David ;

Bajdik, Chris ;

Leung, Samuel ;

McKinney, Steven ;

Chia, Stephen K. ;

Perou, Charles M. ;

Nielsen, Torsten O. .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1368-1376

[10] Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response [J].

de Ronde, Jorma J. ;

Hannemann, Juliane ;

Halfwerk, Hans ;

Mulder, Lennart ;

Straver, Marieke E. ;

Peeters, Marie-Jeanne T. F. D. Vrancken ;

Wesseling, Jelle ;

van de Vijver, Marc ;

Wessels, Lodewyk F. A. ;

Rodenhuis, Sjoerd .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :119-126

← 1 2 3 4 5 6 →